Trillium Therapeutics Inc. Email Format

Biotechnology ResearchMassachusetts, United States11-50 Employees

Trillium Therapeutics Inc. is a clinical-stage biotechnology company focused on cancer immunotherapy. The company concentrates on CD47, a protein that tumors commonly use to dodge immune destruction. Its strategy uses decoy receptors to block the CD47 signal, with the goal of unmasking tumor cells so they can be recognized and eliminated by the immune system.

Headquartered in Cambridge, Massachusetts, the firm operates within the biotechnology research sector and maintains a relatively small team. Its work targets oncology patients by developing therapies intended to overcome tumor immune evasion, with clinicians as the primary practitioners who would implement such treatments upon successful development.

Sign up for free to view info

Company overview Employee directory